FDA 483 - MACSEN DRUGS - September 06, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
MACSEN DRUGS, an API manufacturer in Udaipur, India, received a Form 483 citing significant deficiencies across its quality, laboratory, and production systems. Key issues include releasing fire-impacted products without retesting, inadequate stability testing after chamber failures, and failures in water system requalification and environmental monitoring. The firm also demonstrated poor data integrity practices, an inadequate preventative maintenance program, and insufficient cleaning validation for production equipment.
ID · 54265066-d37e-4490-a3b2-a10d774e5828